Timothy C Burn
Overview
Explore the profile of Timothy C Burn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindley A, Prager G, Bitzer M, Burn T, Lihou C, Croft E
Cancer Res Treat
. 2024 Feb;
56(3):847-855.
PMID: 38351684
Purpose: Pemigatinib is a fibroblast growth factor receptor-2 (FGFR2) inhibitor approved for use in patients with previously treated cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements. This ongoing global Expanded Access...
2.
Zingg D, Bhin J, Yemelyanenko J, Kas S, Rolfs F, Lutz C, et al.
Nature
. 2022 Sep;
609(7929):E13.
PMID: 36050473
No abstract available.
3.
Zingg D, Bhin J, Yemelyanenko J, Kas S, Rolfs F, Lutz C, et al.
Nature
. 2022 Aug;
608(7923):609-617.
PMID: 35948633
Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer. However, clinical responses to FGFR inhibitors...
4.
Neumann O, Burn T, Allgauer M, Ball M, Kirchner M, Albrecht T, et al.
Br J Cancer
. 2022 Jul;
127(8):1540-1549.
PMID: 35871236
Background: Cholangiocarcinoma (CCA) is a primary malignancy of the biliary tract with a dismal prognosis. Recently, several actionable genetic aberrations were identified with significant enrichment in intrahepatic CCA, including FGFR2...
5.
Silverman I, Li M, Murugesan K, Krook M, Javle M, Kelley R, et al.
J Mol Diagn
. 2022 Feb;
24(4):351-364.
PMID: 35176488
Cholangiocarcinoma (CCA) is a heterogeneous biliary tract cancer with a poor prognosis. Approximately 30% to 50% of patients harbor actionable alterations, including FGFR2 rearrangements. Pemigatinib, a potent, selective fibroblast growth...
6.
Wu L, Zhang C, He C, Qian D, Lu L, Sun Y, et al.
J Med Chem
. 2021 Jul;
64(15):10666-10679.
PMID: 34269576
Aberrant activation of FGFR has been linked to the pathogenesis of many tumor types. Selective inhibition of FGFR has emerged as a promising approach for cancer treatment. Herein, we describe...
7.
Silverman I, Hollebecque A, Friboulet L, Owens S, Newton R, Zhen H, et al.
Cancer Discov
. 2020 Nov;
11(2):326-339.
PMID: 33218975
Pemigatinib, a selective FGFR1-3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring fusions/rearrangements, and has gained regulatory approval in the United States....
8.
Liu P, Koblish H, Wu L, Bowman K, Diamond S, DiMatteo D, et al.
PLoS One
. 2020 Apr;
15(4):e0231877.
PMID: 32315352
Alterations in fibroblast growth factor receptor (FGFR) genes have been identified as potential driver oncogenes. Pharmacological targeting of FGFRs may therefore provide therapeutic benefit to selected cancer patients, and proof-of-concept...
9.
Stubbs M, Burn T, Sparks R, Maduskuie T, Diamond S, Rupar M, et al.
Clin Cancer Res
. 2018 Sep;
25(1):300-311.
PMID: 30206163
Purpose: Bromodomain and extraterminal domain (BET) proteins regulate the expression of many cancer-associated genes and pathways; BET inhibitors have demonstrated activity in diverse models of hematologic and solid tumors. We...
10.
Yue E, Sparks R, Polam P, Modi D, Douty B, Wayland B, et al.
ACS Med Chem Lett
. 2017 May;
8(5):486-491.
PMID: 28523098
A data-centric medicinal chemistry approach led to the invention of a potent and selective IDO1 inhibitor , INCB24360 (epacadostat). The molecular structure of INCB24360 contains several previously unknown or underutilized...